Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma Services AG
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Extension study up to three years for secukinumab in psoriatic arthritis
To evaluate the long-term efficacy of secukinumab 75 and 150 mg (provided as pre-filled syringes) with respect to ACR20, ACR50 and ACR70 response over time up to Week 260 in subjects with active psori...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A randomized, open label, parallel-group, international, multicenter study evaluating persistency of response to omalizumab during 32 weeks treatment given as add on to optimized asthma therapy in adult and adolescent patients with severe persistent allergic asthma, who remain inadequately controlled despite GINA (2004) step 4 therapy
To evaluate persistency in treatment responder classification between assessments at 16 and 32 weeks after starting omalizumab therapy given as add on to optimized asthma therapy in patients who remai...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of 12 Week Treatment with Vildagliptin (LAF237) 50 mg QD in Subjects with Impaired Glucose Tolerance (IGT)
To demonstrate the efficacy of vildagliptin in subjects with IGT by testing the hypothesis that vildagliptin 50 mg qd reduces the area under the 0-2 hour prandial plasma glucose curve (AUC0-2hr) more ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Part 1: An open Label Pilot Study to Determine Interstitial and Tissue Concentrations of Aliskiren and Effects on the Renin-Angiotensin System (RAS) in Fat and Skeletal Muscle of Hypertensive Patients with Abdominal Obesity Part 2: A Randomized, Double Blind, 12-weeks Parallel Group Study to Compare Effects of Aliskiren 300 mg and Amlodipine 5 mg on the RAS and Lipid/Carbohydrate Metabolism in Fat and Skeletal Muscle of Hypertensive Patients with Abdominal Obesity
Part 1 - Quantify the concentration of aliskiren, amlodipine and angiotensin II (Ang II) in interstitial fluid (microdialysis), and quantify the concentration of aliskiren, angiotensin II and renin c...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the efficacy and safety of Elidel® Cream 1% in mild to moderate facial atopic dermatitis of patients (2 to 11 years of age, inclusive) intolerant of, or dependent on, topical corticosteroids
To determine the efficacy of Elidel® Cream 1% vs. vehicle on the face of mild to moderate AD patients (2 to 11 years, inclusive) who are intolerant of, or dependent on, topical corticosteroidscorticos...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A multi-part, double blind study to assess safety, tolerability and efficacy of LJN452 in PBC patients
•To determine the effect of LJN452 on cholestatic markers in patients with Primary Biliary Cirrhosis •To determine the safety and tolerability of daily dosing of LJN452 in patients with Primary Bil...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A six-week, randomized, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of the combination of aliskiren 150 mg and amlodipine 5 mg compared to amlodipine 5 mg and 10 mg in hypertensive patients not adequately responsive to amlodipine 5 mg
Evaluate the efficacy of the combination of aliskiren 150 mg and amlodipine 5 mg in patients with essential hypertension not fully responsive to amlodipine 5 mg by testing the hypothesis of superior r...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Study of efficacy and safety of secukinumab compared to ustekinumab in subjects with plaque psoriasis
To demonstrate the superiority of secukinumab compared to ustekinumab in subjects with moderate to severe plaque psoriasis with respect to both PASI 90 and IGA mod 2011 0/1 response at Week 12
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Study of a new drug combination for the treatment of Non Hodgkin’s Lymphoma
• To establish effectiveness of ofatumumab in combination with bendamustine in patients with indolent B-cell NHL disease relapsed after rituximab therapy.
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
NeoALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study A randomized, multicentre open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer
To evaluate and compare the rate of pathological complete response (pCR) at the time of surgery in patients with ErbB2 overexpressing or amplified operable breast cancer randomised between the study t...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
15
16
17
18
19
20
21
22
23
24
Next